Reversible ocular myasthenia gravis or mitochondrial myopathy from statins?

被引:8
作者
Engel, WK [1 ]
机构
[1] Good Samaritan Hosp, USC Keck Sch Med, Neuromuscular Ctr, Los Angeles, CA 90017 USA
关键词
D O I
10.1016/S0140-6736(03)12152-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:85 / 86
页数:2
相关论文
共 5 条
[1]   Safety of HMG-CoA reductase inhibitors: Focus on atorvastatin [J].
Bernini, F ;
Poli, A ;
Paoletti, R .
CARDIOVASCULAR DRUGS AND THERAPY, 2001, 15 (03) :211-218
[2]  
Engel WK., 1971, EXCERPTA MED INT C S, V237, P28
[3]   Statins, fibrates, and ocular myasthenia [J].
Parmar, B ;
Francis, PJ ;
Ragge, NK .
LANCET, 2002, 360 (9334) :717-717
[4]   HMG-CoA reductase inhibitors and myotoxicity [J].
Ucar, M ;
Mjörndal, T ;
Dahlqvist, R .
DRUG SAFETY, 2000, 22 (06) :441-457
[5]  
WARMOLTS JR, 1970, LANCET, V2, P1198